Funding for this research was provided by:
University of Innsbruck and Medical University of Innsbruck
Article History
Received: 14 September 2021
Accepted: 3 January 2022
First Online: 8 February 2022
Conflict of interest
: H. Hegen has participated in meetings sponsored by, received speaker honoraria or travel funding from Bayer, Biogen, Merck, Novartis, Sanofi-Genzyme, Siemens, Teva, and received honoraria for acting as consultant for Biogen, Novartis and Teva. K. Berek has participated in meetings sponsored by and received travel funding from Roche, Teva and Biogen. F. Deisenhammer has participated in meetings sponsored by or received honoraria for acting as an advisor/speaker for Alexion, Almirall, Biogen, Celgene, Genzyme-Sanofi, Merck, Novartis Pharma, Roche, and Teva. His institution has received research grants from Biogen and Genzyme Sanofi. He is section editor of the MSARD Journal (Multiple Sclerosis and Related Disorders).